NYSE American - Delayed Quote USD

Xtant Medical Holdings, Inc. (XTNT)

0.9500

+0.0485

(+5.38%)

At close: April 26 at 3:59 PM EDT

0.9500

0.00

(0.00%)

After hours: April 26 at 6:19 PM EDT

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% y

GlobeNewswire 26 days ago
Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host

GlobeNewswire last month
Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company’s revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended to increase the commitment from $8.0 million to $17.0 million. The Company’s term loan was also amended to provide for an additional $10.0 million tranche, to be made available f

GlobeNewswire last month
Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference

BELGRADE, Mont., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference, to be held on Monday, March 4, 2024 at 12:50 p.m. Eastern Time in Boston. A live webcast of the presentation will be available on the Investors section of the Company’s

GlobeNewswire last month
Xtant Medical to Participate in Upcoming Investor Conferences

BELGRADE, Mont., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences: Canaccord Genuity 2024 Musculoskeletal Conference – February 12 Sean Browne, President and CEO, will present on Monday, February 12 at 9:00 AM PT / 12:00 PM ET and participate in 1x1 meetings with institut

GlobeNewswire 2 months ago
Xtant Medical Announces Record Third Quarter Revenue of $25 Million

Raises 2023 Annual Revenue Guidance to $88 Million - $91 MillionBELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2023. “Driven by strong organic growth of 18%, and contributions from our recent acquisitions, we achieved record third quarter revenue of

GlobeNewswire 5 months ago
Xtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023

BELGRADE, Mont., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, before the open of the financial markets on Thursday, November 9, 2023. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a confere

GlobeNewswire 5 months ago
Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

Expands Xtant’s Manufacturing Capabilities and Capacity to Drive Growth BELGRADE, Mont., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired the nanOss production operations from RTI Surgical, Inc., a leading CDMO in regenerative medicine. Under the terms of the purchase agreement, Xtant acquired certain assets, including

GlobeNewswire 6 months ago
Xtant Medical Highlights Growing Product Portfolio at NASS 2023

BELGRADE, Mont., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it will exhibit its suite of orthobiologics and spinal fixation products at the North American Spine Society (NASS) 2023 Annual Meeting, which will be held October 18-21 at the Los Angeles Convention Center in Los Angeles, CA. “In recent years, we have dramatically expanded o

GlobeNewswire 6 months ago
Xtant Medical Completes Acquisition of Surgalign’s Hardware and Biologics Business

BELGRADE, Mont., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it completed the acquisition of certain assets and liabilities related to the domestic and international biologics and spinal fixation offerings of Surgalign Holdings, Inc. under a Bankruptcy Court supervised process for $5 million, plus assumed liabilities, in an all-ca

GlobeNewswire 8 months ago
Xtant Medical Announces Second Quarter Revenue Growth of 32%

Raises 2023 Annual Revenue Guidance to $75 Million - $77 Million BELGRADE, Mont., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2023. “In the second quarter, we achieved strong revenue growth on both a sequential and annual basis driven by our core biologics and fixatio

GlobeNewswire 8 months ago
Xtant Medical Wins Auction for Surgalign’s Hardware and Biologics Business

Acquisition to Enhance Xtant’s Growing Spinal Fusion Devices Portfolio BELGRADE, Mont., July 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it was the successful bidder for certain assets and liabilities related to the domestic and international biologics and spinal fixation offerings of Surgalign Holdings, Inc. Xtant’s initial bid, as se

GlobeNewswire 8 months ago
Xtant Medical to Issue Second Quarter 2023 Financial Results on August 1, 2023

BELGRADE, Mont., July 25, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2023, before the open of the financial markets on Tuesday, August 1, 2023. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference cal

GlobeNewswire 8 months ago
Xtant Medical Announces Closing of $15 Million Private Placement

BELGRADE, Mont., July 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $15 million private placement with accredited investors. The Company sold 20 million shares of common stock at a purchase price of $0.75 per share. After deducting fees and other estimated offering expenses, the Company received net pro

GlobeNewswire 9 months ago
Xtant Medical Announces $15 Million Private Placement

BELGRADE, Mont., July 03, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with accredited investors to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 20,000,000 shares of common stock at a purchase price of $0.75 per share, resulting in gross pr

GlobeNewswire 9 months ago
Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. “We are pleased to welcome Lori to our Board, marking another high

GlobeNewswire 11 months ago
Xtant Medical Announces First Quarter 2023 Revenue Growth of 38% and Full Year 2023 Revenue Guidance

Initiates Annual Revenue Guidance of $73 Million - $75 Million in Full Year 2023 BELGRADE, Mont., May 04, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2023. The Company also introduced financial guidance for the full year 2023. “Highlighted by solid revenue growth and the Cofle

GlobeNewswire 11 months ago

Performance Overview

Return	XTNT	S&P 500
YTD	-15.93%	+6.92%
1-Year	+55.74%	+25.26%
3-Year	-53.20%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Xtant Medical Holdings, Inc. (XTNT)

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference

Xtant Medical to Participate in Upcoming Investor Conferences

Xtant Medical Announces Record Third Quarter Revenue of $25 Million

Xtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023

Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

Xtant Medical Highlights Growing Product Portfolio at NASS 2023

Xtant Medical Completes Acquisition of Surgalign’s Hardware and Biologics Business

Xtant Medical Announces Second Quarter Revenue Growth of 32%

Xtant Medical Wins Auction for Surgalign’s Hardware and Biologics Business

Xtant Medical to Issue Second Quarter 2023 Financial Results on August 1, 2023

Xtant Medical Announces Closing of $15 Million Private Placement

Xtant Medical Announces $15 Million Private Placement

Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

Xtant Medical Announces First Quarter 2023 Revenue Growth of 38% and Full Year 2023 Revenue Guidance

Performance Overview